Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of oral paricalcitol on endothelial function and FGF-23 in peritoneal dialysis patients
2012-002744-24Phase 4Completed
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of paricalcitol in chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and end-stage kidney disease (ESKD) (2 arms), sponsored by Policlinico Gemelli. Primary endpoints: Change in post-ischemic brachial artery dilatation from baseline to 6 months and Change in FGF-23 from baseline to 6 months. Started Oct 2012; status: completed.
02
Drugs
paricalcitol
03
Conditions
chronic kidney disease (CKD)secondary hyperparathyroidism (SHPT)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2012-002744-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002744-24.